Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators?
Nat Clin Pract Oncol
.
2006 Mar;3(3):134-5.
doi: 10.1038/ncponc0444.
Authors
Rachel Schiff
1
,
Adrian V Lee
Affiliation
1
Breast Center at Baylor College of Medicine, Houston, TX 77030, USA. rschiff@breastcenter.tmc.edu
PMID:
16520802
DOI:
10.1038/ncponc0444
No abstract available